摘要
目的 探讨噻托溴铵治疗稳定期慢性阻塞性肺疾病（COPD）的疗效.方法 回顾性分析240例稳定期COPD患者的临床资料.根据治疗方法分为噻托溴铵组和异丙托溴铵组,每组120例.比较治疗前和治疗2周后肺功能及临床症状改善情况.结果 噻托溴铵组的肺功能指标一秒用力呼气量（FVC）,用力肺活量（FEV1）、FEV1/FVC及FEV1占预计值的百分比分别为（3.64±0.58）L、（2.53±0.25）L、（62.40±9.42）%、（58.24±4.83）%,均较异丙托溴铵组的（3.14±0.36）L、（1.91±0.23）L、（56.50±7.36）%、（50.41±5.54）%明显改善（t=2.037、1.875、2.616、2.945,均P〈0.05）,且前者的临床症状亦比后者改善明显,差异有统计学意义（H=5.990,P〈0.05）.结论 噻托溴铵治疗治疗稳定期COPD,具有良好的临床效果,值得临床推广应用.
Objective To explore the clinical effect of inhaling tiotropium in treatment of patients with stable chronic obstructive pulmonary disease.Methods The clinical data of 240 patients with stable chronic obstructive pulmonary disease were retrospectively analyzed,and they were divided into two groups,the group treated with tiotropium and the group treated with ipratropium bromide（n = 120 in each group）.The lung function was detected 2 weeks before and after the treatment, and the clinical symptoms were observed.Results FVC, FEV1, FEV1/FVC, and FEV1/predictive value of the tiotropium group were（3.64 ±0.58） L, （2.53 ±0.25） L, （62.40 ±9.42）% ,（58.24 ± 4.83）% respectively,much higher than（3.14 ±0.36）L,（ 1.91 ±0.23）L,（56.50 ±7.36）%,（50.41 ±5.54）% of the ipratropium bromide group（t =2.037,1.875,2.616,2.945,all P〈0.05） ,and the clinical symptoms were better changed in tiotropium group than in ipratropium bromide group （H = 5.990, P 〈 0.05 ）.Conclusion Tiotropium could effectively improve lung function and clinical symptoms in patients with stable COPD.
出处
《中国基层医药》
CAS
2011年第12期1608-1609,共2页
Chinese Journal of Primary Medicine and Pharmacy
